213 related articles for article (PubMed ID: 35579421)
1. Promyelocytic leukemia nuclear body-like structures can assemble in mouse oocytes.
Udagawa O; Kato-Udagawa A; Hirano S
Biol Open; 2022 Jun; 11(6):. PubMed ID: 35579421
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
Hirano S; Udagawa O
Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
[TBL] [Abstract][Full Text] [Related]
3. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
4. A Tale of Usurpation and Subversion: SUMO-Dependent Integrity of Promyelocytic Leukemia Nuclear Bodies at the Crossroad of Infection and Immunity.
Patra U; Müller S
Front Cell Dev Biol; 2021; 9():696234. PubMed ID: 34513832
[TBL] [Abstract][Full Text] [Related]
5. The promyelocytic leukemia protein isoform PML1 is an oncoprotein and a direct target of the antioxidant sulforaphane (SFN).
Alhazmi N; Pai CP; Albaqami A; Wang H; Zhao X; Chen M; Hu P; Guo S; Starost K; Hajihassani O; Miyagi M; Kao HY
Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118707. PubMed ID: 32243901
[TBL] [Abstract][Full Text] [Related]
6. PML nuclear body-residing proteins sequentially associate with HPV genome after infectious nuclear delivery.
Guion L; Bienkowska-Haba M; DiGiuseppe S; Florin L; Sapp M
PLoS Pathog; 2019 Feb; 15(2):e1007590. PubMed ID: 30802273
[TBL] [Abstract][Full Text] [Related]
7. The SUMO protease SENP6 is a direct regulator of PML nuclear bodies.
Hattersley N; Shen L; Jaffray EG; Hay RT
Mol Biol Cell; 2011 Jan; 22(1):78-90. PubMed ID: 21148299
[TBL] [Abstract][Full Text] [Related]
8. Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
Hirano S; Udagawa O
PLoS One; 2022; 17(5):e0268835. PubMed ID: 35594310
[TBL] [Abstract][Full Text] [Related]
9. SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
El McHichi B; Regad T; Maroui MA; Rodriguez MS; Aminev A; Gerbaud S; Escriou N; Dianoux L; Chelbi-Alix MK
J Virol; 2010 Nov; 84(22):11634-45. PubMed ID: 20826694
[TBL] [Abstract][Full Text] [Related]
10. The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.
Schilling EM; Scherer M; Reuter N; Schweininger J; Muller YA; Stamminger T
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903803
[TBL] [Abstract][Full Text] [Related]
11. SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1.
Brown JR; Conn KL; Wasson P; Charman M; Tong L; Grant K; McFarlane S; Boutell C
J Virol; 2016 Jul; 90(13):5939-5952. PubMed ID: 27099310
[TBL] [Abstract][Full Text] [Related]
12. PML nuclear bodies and chromatin dynamics: catch me if you can!
Corpet A; Kleijwegt C; Roubille S; Juillard F; Jacquet K; Texier P; Lomonte P
Nucleic Acids Res; 2020 Dec; 48(21):11890-11912. PubMed ID: 33068409
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
14. Identification of RNF168 as a PML nuclear body regulator.
Shire K; Wong AI; Tatham MH; Anderson OF; Ripsman D; Gulstene S; Moffat J; Hay RT; Frappier L
J Cell Sci; 2016 Feb; 129(3):580-91. PubMed ID: 26675234
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional organization of promyelocytic leukemia nuclear bodies.
Lang M; Jegou T; Chung I; Richter K; Münch S; Udvarhelyi A; Cremer C; Hemmerich P; Engelhardt J; Hell SW; Rippe K
J Cell Sci; 2010 Feb; 123(Pt 3):392-400. PubMed ID: 20130140
[TBL] [Abstract][Full Text] [Related]
16. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.
Van Damme E; Laukens K; Dang TH; Van Ostade X
Int J Biol Sci; 2010 Jan; 6(1):51-67. PubMed ID: 20087442
[TBL] [Abstract][Full Text] [Related]
17. Solubility changes of promyelocytic leukemia (PML) and SUMO monomers and dynamics of PML nuclear body proteins in arsenite-treated cells.
Hirano S; Udagawa O; Kobayashi Y; Kato A
Toxicol Appl Pharmacol; 2018 Dec; 360():150-159. PubMed ID: 30292834
[TBL] [Abstract][Full Text] [Related]
18. Viral DNA Binding Protein SUMOylation Promotes PML Nuclear Body Localization Next to Viral Replication Centers.
Stubbe M; Mai J; Paulus C; Stubbe HC; Berscheminski J; Karimi M; Hofmann S; Weber E; Hadian K; Hay R; Groitl P; Nevels M; Dobner T; Schreiner S
mBio; 2020 Mar; 11(2):. PubMed ID: 32184235
[TBL] [Abstract][Full Text] [Related]
19. Myogenic differentiation triggers PML nuclear body loss and DAXX relocalization to chromocentres.
Salsman J; Rapkin LM; Margam NN; Duncan R; Bazett-Jones DP; Dellaire G
Cell Death Dis; 2017 Mar; 8(3):e2724. PubMed ID: 28358373
[TBL] [Abstract][Full Text] [Related]
20. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
